Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.
Oncolytic viruses (OVs) are novel immunotherapeutic agents whose anticancer effects come from both oncolysis and elicited antitumor immunity. OVs induce mostly immunogenic cancer cell death (ICD), including immunogenic apoptosis, necrosis/necroptosis, pyroptosis, and autophagic cell death, leading to exposure of calreticulin and heat-shock proteins to the cell surface, and/or released ATP, high-mobility group box 1, uric acid, and other damage-associated molecular patterns as well as pathogen-associated molecular patterns as danger signals, along with tumor-associated antigens, to activate dendritic cells and elicit adaptive antitumor immunity. Dying the right way may greatly potentiate adaptive antitumor immunity. The mode of cancer cell death may be modulated by individual OVs and cancer cells as they often encode and express genes that inhibit/promote apoptosis, necroptosis, or autophagic cell death. We can genetically engineer OVs with death-pathway-modulating genes and thus skew the infected cancer cells toward certain death pathways for the enhanced immunogenicity. Strategies combining with some standard therapeutic regimens may also change the immunological consequence of cancer cell death. In this review, we discuss recent advances in our understanding of danger signals, modes of cancer cell death induced by OVs, the induced danger signals and functions in eliciting subsequent antitumor immunity. We also discuss potential combination strategies to target cells into specific modes of ICD and enhance cancer immunogenicity, including blockade of immune checkpoints, in order to break immune tolerance, improve antitumor immunity, and thus the overall therapeutic efficacy.
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Zong Sheng
ZS
Guo
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Zuqiang
Z
Liu
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
David L
DL
Bartlett
DAMPs; PAMP; antitumor immunity; autophagy; cross-presentation; immune tolerance; immunogenic cancer cell death; tumor-associated antigen